PharmEasy Unlisted Shares | API Holdings Unlisted Shares

Buy PharmEasy Unlisted Shares | PharmEasy Unlisted Share Price | API Holdings Share Price

Buy Now

PharmEasy Unlisted Shares Price
₹7.25 Per Equity Share
Sector: Online Pharmacy Platform
Lot Size: 2000 shares
Note: Stock prices are subject to change and may not reflect real-time values.

 PharmEasy Unlisted Shares Details

NameAPI Holdings Limited Unlisted Shares
Alias NamePharmEasy Unlisted Shares
SectorOnline Pharmacy Platform
Security TypePre-IPO/Unlisted Equity Shares
Face Value₹1
ISIN CodeINE0DJ201029
Available in DepositoryCDSL & NSDL
Pharmeasy Unlisted Share Price₹7.25 Per Equity Share
Lot Size2000 Shares
Minimum Investment₹14500
All Time High ₹135
All Time Low₹7
Highlights- India's Largest Digital Healthcare Platform
- 25 mn+ registered users
PANAASCA1201E
*Rates and lot size mentioned above for Pharmeasy Unlisted Shares are indicative and subject-to change. Kindly check the latest rates of Pharmeasy Unlisted Shares with us.

 About Company:

API Holdings (owner of PharmEasy) is India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021), according to RedSeer Report. API Holdings operate as an integrated, end-to-end business that aims to provide solutions for healthcare needs of consumers across the following critical stages
A. providing digital tools and information on illness and wellness,
B. offering teleconsultation,
C. offering diagnostics and radiology tests, and
D. delivering treatment protocols including products and devices.

API Holdings has custom-built proprietary technology, unified data platforms, supply chain capabilities, and deep understanding of the dynamic interplay between the various sub-segments of India’s healthcare market are the capabilities that differentiate them.

These capabilities enable them to provide each stakeholder in the healthcare value-chain, viz.:
(a) channel (wholesalers, retailers and chemists / institutions),
(b) consultants (and hospitals), diagnostic and radiology labs,
(c) consumers, and
(d) companies (pharmaceutical, nutraceutical, medical devices)
with the technology tools and capabilities to solve their challenges, while also enabling them to benefit from an interconnected network. At the same time, they also enable them to build a scaled presence, allowing their platform to reach a wide base of stakeholders across the length and breadth of this country. Their businesses have a presence across the country, with last-mile 163 capabilities to deliver in over 18,587 pin codes (for June 2021) via PharmEasy marketplace, allowing them the ability to provide access in an affordable manner to the common man. Their platforms have scaled across urban, semi-urban and rural India, with an ability to serve people across income groups and geographies.

pharmeasy unlisted sharesSource: PharmEasy IPO DRHP
pharmeasy unlisted sharesSource: PharmEasy IPO DRHP
pharmeasy unlisted shares PharmEasy Unlisted Shares - Business Overview

PharmEasy:
PharmEasy is a consumer healthcare “super app”.
PharmEasy is a consumer healthcare “super app” that provides consumers with on-demand, home delivered access to a wide range of prescription, OTC pharmaceutical, other consumer healthcare products, comprehensive diagnostic test services, and teleconsultations thereby serving their healthcare needs.
25 Million+Total Users
8.8 million+Total Orders
2.4 million+Transacting Customers

Services offered by PharmEasy:

  • Order Medicines
  • Healthcare Products
  • Diagnostic Tests

pharmeasy unlisted sharesSource: PharmEasy IPO DRHP

API Holdings: Business & Brands:

pharmeasy unlisted shares. business and brands under api holdings

  • Aknamed: Tech-enabled Hospital Supplies Procurement
  • Docon: EMR and Practice Management Software for Clinics & Doctors
  • Pharmeasy: India’s Largest Online Pharmacy Marketplace
  • Retailio: One of India’s Largest Pharma Platform connecting Pharmacies with Wholesalers
  • Thyrocare: India’s Largest Diagnostics Test Provider by Volumes

API Holdings (PharmEasy) Financial Review: Strategic Focus on Efficiency and Margin Improvement in Fiscal 2024:

In response to capital constraints throughout the year, API Holdings (PharmEasy) has strategically concentrated on sustainable revenue growth by prioritizing quality and enhancing the consumer experience.

  • Emphasis on Quality: API Holdings has reinforced its commitment to quality across all business segments. Notably, 25 out of 30 diagnostic labs of API Holdings are NABL accredited, provided to the top 2% of labs in India.
  • Targeting High-Value Customers: Within the PharmEasy platform, efforts to acquire and retain high lifetime value customers have been successful, leading to a more than 20% increase in average order value. Additionally, Pharmeasy has intensified its focus on securing more profitable clients in both the hospital and retail sectors.
  • Maximizing Capacity Utilization: API Holdings has improved the capacity utilization of its fulfillment and warehousing infrastructure by rationalizing and integrating its supply chain across the country.
  • Enhancing Wallet Share: A concerted effort has been made by API Holdings to increase wallet share within the existing chemist and hospital business by enhancing customer experience and value propositions.
  • Margin Enhancement: API Holdings has strategically optimized its product mix by emphasizing higher-margin products, particularly its own private label brands. There has also been a deliberate shift in the sales mix to prioritize comprehensive care opportunities, such as providing diagnostic services to current medicine customers.
  • Cost Optimization: Significant employee expense optimization has occurred through refining supply chain, back-office, and technology staffing. Other costs have also been rationalized, including a strategic reduction in marketing expenses to focus on high-value, lifetime revenue customers, along with cuts in brand-related expenditures.
  • Cash Conservation: API Holdings has focused on optimizing working capital through better inventory management and improved collection processes, especially within the chemist and hospital business.

These strategic actions highlight API Holdings’ commitment to financial prudence, operational efficiency, and sustained value creation. In our view, these measures lay a strong foundation for a resilient and agile financial future.

PharmEasy Unlisted Shares-Key Financial Graphs

PharmEasy Unlisted Shares - Revenue from Operations PharmEasy Unlisted Shares - Total Expenses PharmEasy Unlisted Shares - Profit-Loss

API Holdings – PharmEasy Rights Issue Details:

API Holdings – PharmEasy Rights Issue (2023):

  • Type of Instrument: Series B CCPS
  • API Holdings Rights Issue Price: INR 96.8 (including a premium of INR 95.8) such that the effective price per equity share issued pursuant to conversion of CCPS B is INR 4.84 (Rupees Four and Eighty Four Paise) per CCPS B (which translates into a conversion of 20 (twenty) Equity Shares for every 1
    (one) CCPS B)
  • Every 17 (seventeen) equity shares held by an Eligible Equity Shareholder would entitle the shareholder to receive 20 (twenty) additional equity shares upon conversion of each CCPS B that it subscribes to in the Rights Issue at the issue price of INR 96.8 (Rupees ninety-six and eighty paise)
  • In other words, every 17 (seventeen) equity shares held by an Eligible Equity Shareholder
    would entitle the shareholder to receive 20 (twenty) additional equity shares upon conversion of each CCPS B that it subscribes to in the Rights Issue at the issue price of INR 96.8

API Holdings Right Issue of CCPS (2022):

Key Parameters of PharmEasy Rights Issue indicated by the company:

  • Type of Instrument: Compulsory Convertible Preference Shares (CCPS)
  • Issue Price: Expected to be around ₹100 per CCPS
  • Estimated Timeline: The rights issue will be opened for a period of 30 days, starting from on or around the first week of September

Know more about API Holdings (PharmEasy) Rights Issue-2022 in detail by reading our blog post here.

 API Holdings – PharmEasy Financials

Financial in Millions unless specifically mentioned
Particulars2023-242022-232021-222020-212019-20
Revenue from operations56,642.8666,439.3857,288.2123,352.696,675.42
Other income946.55558.33521.81253.93699.06
Total income57,589.4166,997.7157,810.0223,606.627,374.48
Cost of materials consumed1,645.091,569.20854.60--
Purchase of stock-in-trade45,728.0655,120.6052,566.12 22,668.176,991.24
Changes in inventories of stock-in-trade1,430.14618.96(2,290.53)(1,143.95)(582.38)
Employee benefits expense 6,993.6312,833.2014,589.712,702.941,371.90
Finance costs7,279.166,655.432,582.64434.31118.86
Depreciation and amortisation expense2,159.522,434.401,587.85329.01187.71
Expected Credit Loss on Financial Assets1,692.64683.37
Other expenses5,619.769,824.9415,025.514,818.802,756.71
Total expenses72,548.0089,740.1084,915.9029,809.2810,844.04
Loss before tax(25,219.72)(51,965.22)(39,707.70) (6,202.66)(3,469.56)
Loss after tax(25,335.13)(52,117.34)(39,924.96)(6,413.36)(3,352.79)
EPS (In INR)(4.07)(8.51)(7.28)(2.67)(1.29)

 PharmEasy Unlisted Shares Price Chart

*Rates mentioned in the chart are indicative.

 PharmEasy Unlisted Shares Trend

Trend

Trend Identifier

Extremely Bullish
Bullish
Neutral
Bearish
Extremely Bearish

The trend indicator above has been derived from the current demand/supply of PharmEasy Unlisted Shares. The trend has a tendency to change anytime depending on the market conditions and other events. This indicator must not be construed as any recommendation to buy/sell/hold.

 PharmEasy Unlisted Shares – Valuation (Market Capitalisation)

Total Number of Outstanding Shares: 6,24,04,35,432 equity shares + ~ 1257430527 (on conversion of Series A CCPS) + ~ 4034249520 (on conversion of Series B CCPS)
= Approx. shares after all conversion: 11532115479 shares

Market Cap Scenarios:

At 8 Rs/Share, PharmEasy Unlisted Shares values the company at approx. Rs. 9,225 crores.

This are just pre-defined scenarios, since the market cap is variable to price, you can calculate the latest market cap based on the ongoing rates of pharmeasy unlisted shares.

At 10 Rs/Share, PharmEasy Unlisted Shares values the company at approx. Rs. 11,532 crores.

This are just pre-defined scenarios, since the market cap is variable to price, you can calculate the latest market cap based on the ongoing rates of pharmeasy unlisted shares.

At 12 Rs/Share, PharmEasy Unlisted Shares values the company at approx. Rs. 13,838 crores.

This are just pre-defined scenarios, since the market cap is variable to price, you can calculate the latest market cap based on the ongoing rates of pharmeasy unlisted shares.

 API Holdings – Pharmeasy Key Shareholding

Source: PharmEasy Annual Report

 API Holdings (Pharmeasy) Peers

Below are the comparable peers with business models that are nearly identical to API Holdings (Pharmeasy).
The peers mentioned have a similar line of business and may not be comparable on an apple-to-apple basis.
Name Listing Status
Tata 1mgUnlisted
NetmedsUnlisted
Apollo Hospitals (Apollo Pharmacy)Listed

 API Holdings (PharmEasy) Corporate Actions

Dividend

No information found for API Holdings (PharmEasy) Dividend

Rights

API Holdings (PharmEasy) Rights Issue

  • FY2023-24:

    • Type of Instrument: Series B CCPS
    • API Holdings Rights Issue Price: INR 96.8 (including a premium of INR 95.8) such that the effective price per equity share issued pursuant to conversion of CCPS B is INR 4.84 (Rupees Four and Eighty Four Paise) per CCPS B (which translates into a conversion of 20 (twenty) Equity Shares for every 1
      (one) CCPS B)
    • Every 17 (seventeen) equity shares held by an Eligible Equity Shareholder would entitle the shareholder to receive 20 (twenty) additional equity shares upon conversion of each CCPS B that it subscribes to in the Rights Issue at the issue price of INR 96.8 (Rupees ninety-six and eighty paise)
    • In other words, every 17 (seventeen) equity shares held by an Eligible Equity Shareholder
      would entitle the shareholder to receive 20 (twenty) additional equity shares upon conversion of each CCPS B that it subscribes to in the Rights Issue at the issue price of INR 96.8
  • FY2022-23: API Holdings (PharmEasy) declared Rights issue @ Rs.100 per CCPS. Record date for Rights Issue was September 9, 2022.

Buyback

No information found for API Holdings (PharmEasy) Buyback

Split

API Holdings (PharmEasy) shares face value split:

  • API Holdings (PharmEasy) approved the sub-division of shares from face value Rs.10 to Rs.1. the record date for the same was 29th October, 2021

 Unlisted Arena Review: API Holdings (PharmEasy) Unlisted Shares

API Holdings (PharmEasy) Financial Overview: Focus on Strategic Efficiency and Margin Improvement

  • In Fiscal 2024, API Holdings (PharmEasy) concentrated on attracting higher-margin customers while maximizing the efficiency of its existing warehouse facilities, sales infrastructure, and marketing expenditures. This focus led to a 14.7% decrease in revenue from operations, amounting to INR 56,642.86 million, down from INR 66,439.38 million in Fiscal 2023, affecting both sales of goods and services.

    Revenue Breakdown:

  • Sales to Retailers: There was a 15.50% decline in revenue from goods sold, largely due to a strategic optimization of new customer acquisition on the PharmEasy platform and reduced marketing spend, which shifted the focus toward improving average order values and unit economics.
  • Sales to Hospitals: Revenue dropped as PharmEasy chose to forgo lower-margin clients that required significant working capital. Instead, API Holdings enhanced service levels through improved fulfillment and faster delivery, ultimately increasing wallet share.
  • Sales to Chemists/Institutions: A slight decline was observed due to temporary working capital constraints, which were later addressed through a successful rights issue.

    The revenue from services, particularly through Thyrocare and API diagnostics, showed growth, with Thyrocare’s performance improving by 7.7% in Fiscal 2024, driven by the addition of over 200 new tests and an expanded franchise network.

Margin and Expense Optimization: API Holdings improved its EBITDA before exceptional items and ESOP expenses to (7.5%) of revenue, up from (12.0%) in Fiscal 2023, thanks to several cost optimization strategies:

  • Employee Benefit Expenses: Costs were reduced through centralization and optimization of the operational team, closure of non-profitable warehouses, and rationalization of support functions.
  • Sales Promotion and Marketing Expenses: These decreased from 3.5% of revenue in Fiscal 2023 to 0.4% in Fiscal 2024, reflecting a targeted approach toward high-lifetime value customers and a focus on efficient marketing channels.
  • Other Expenses: There were notable reductions in costs related to legal, professional, IT, and miscellaneous expenses.

ESOP and Exceptional Items:

  • ESOP Expenses: API Holdings incurred INR 2,218.52 million in ESOP expenses (FY 23: INR 6,237.50 million)
  • Impairment Charges: API Holdings recorded an impairment charge of INR 6,549.94 million (FY 23: INR 29,219.84 million) primarily related to retailer operations.
  • Other Exceptional Items: Early redemption charges of INR 3,424.94 million for NCDs and adjusted consideration charges of INR 295 million were recognized in relation to the Medlife acquisition.

Loss Overview: The loss before exceptional items and tax improved to -26.4% of revenue in Fiscal 2024, compared to -34.2% in Fiscal 2023, primarily due to cost rationalization and an emphasis on expanding gross margins. When factoring in exceptional items, the total loss for the year as a percentage of revenue stood at 44.7% in Fiscal 2024, down from 78.4% the previous year.

Cash Flow Management: Pharmeasy demonstrated prudent cash management, with net cash outflow from operating activities decreasing significantly from INR 7,465.86 million in FY23 to INR 611.34 million in FY24. The increase in cash flow was bolstered by proceeds from the rights issue amounting to INR 20,000 million received during the year.

Overall, API Holdings (PharmEasy) is focused on creating a more resilient and efficient financial structure, setting the stage for future growth and value creation.

Disclaimer: Please note that the above review is about the API Holdings (PharmEasy) Unlisted Shares trading in the unlisted space and not about the company itself. The views are purely personal and must not be construed as any recommendation/advice to buy/sell/hold. The figures and calculations are presented in good faith and we are not liable for any errors in the same. Kindly do your due diligence before investing.

 API Holdings – PharmEasy IPO DRHP

 API Holdings – PharmEasy News

Buy PharmEasy unlisted shares

 FAQ for PharmEasy Unlisted Shares

How to buy PharmEasy Unlisted Shares?

Process of Buying PharmEasy Unlisted Shares

  • Get connected with us and inquire for the PharmEasy Unlisted Shares
  • We will quote the current prevailing market rates of the PharmEasy Unlisted Shares (Subject to availability)
  • If you agree on the rate and quantity, we will send our bank details. (Please note, we accept payment only through bank)
  • Buyer transfers the fund in our bank account and buyer also need to send their demat details (for initiating share transfer process)
  • Post receiving funds and demat details, we initiate transfer of PharmEasy unlisted shares. The shares usually gets transferred on same/next working day in your demat account

For detailed buying process, refer here

What is the minimum lot size for buying PharmEasy Unlisted Shares?

The minimum lot size for investing in PharmEasy Unlisted Shares is 500 Shares

What is the lock-in period for PharmEasy Unlisted Shares?

The Lock-in period for PharmEasy Unlisted Shares will be Six Months. The Lock-in period starts from the date of IPO allotment. (According to DRHP)

What happens after the lock-in period gets completed?

As per the SEBI guidelines, lock-in period for Pre IPO shares is six months. The lock-in period starts from the date of allotment of IPO. During the lock-in period, the shares remain in your account but are marked as locked. After six months, the shares automatically gets unlocked and one can sell it normally on stock exchanges like any other listed shares

Is buying PharmEasy Unlisted Shares Legal?

Yes, buying PharmEasy Unlisted Shares is completely legal

How to check price of PharmEasy Unlisted Shares?

You can regularly check the updated price of PharmEasy Unlisted Shares at our Website and on our Telegram Channel

When can we expect IPO of PharmEasy (API Holdings Limited)?

The IPO of PharmEasy (API Holdings Limited) can be expected in medium to long term.

Where to buy PharmEasy Unlisted Shares?

At Unlisted Arena, you can buy PharmEasy Unlisted Shares and many such Pre IPO Shares easily at most reasonable rates with a hassle-free process. Unlisted Arena is India’s leading dealer in Unlisted & Pre IPO Shares

How to sell PharmEasy Unlisted Shares?

You can sell PharmEasy Unlisted Shares:

Before IPO: You can sell PharmEasy Unlisted Shares before IPO too. You need to have a buyer for this shares. We can also help you to liquidate your holdings of unlisted shares.

After IPO: Once the lock-in period is complete, you can sell the shares on stock exchanges(NSE/BSE) just like any other listed shares.

How to transfer PharmEasy Unlisted Shares?

There are two methods to transfer PharmEasy Unlisted Shares
Method 1 – Offline Transfer

In this method, you must have a Delivery Instruction Slip (DIS) book which is provided by your broker. All the demat broking companies have its own DIS book. Along with DIS, there is an annexure which is to be submitted by the seller. Annexure too is provided by the demat broking company. After filing DIS and annexure, duly signed by the seller, they are to be handed over to your respective broker. Post that, your broker will process the request and transfer the shares as per details provided

Method 2 – Online Transfer

One can also transfer shares online through E-DIS/Off Market share transfer. The client must check with their respective brokers if they provide such facility. One can also transfer shares through CDSL easiest (for CDSL Demat) and NSDL Speed-E (For NSDL Demat) after registering into it.

Are API Holdings Unlisted Shares in demat form?

Yes, API Holdings Unlisted Shares are in demat form just like listed shares. You can buy and store them in your demat account. Like listed shares, Unlisted Shares also have their ISIN code so that you can verify the authenticity of shares.

Where will be PharmEasy Unlisted Shares/Pre IPO shares be reflected?

Once the process is complete, PharmEasy Unlisted Shares will reflect in your demat account. The shares usually gets reflected in your Depository holdings (DP Holdings). You can check it in your stock brokers app/website. The shares are also shown on your DP transactions and holding statement.

You can also check your holdings in the following:

If you have CDSL Demat Account – CDSL Myeasi app

If you have NSDL Demat Account – NSDL Speed-E

Many investors do ask ‘How to buy PharmEasy Unlisted Shares in Zerodha, Angel One, Upstox, etc?’
You can buy PharmEasy Unlisted Shares in any demat account with any broking company

How much time will it take to get PharmEasy Unlisted Shares credited in my demat account?

When it comes to delivery of unlisted shares- Be assured as Unlisted Arena is the fastest in delivering shares. Once the process is completed, we usually deliver the shares on same day or the next working day. i.e T day or (T+1) working day.

How much STCG tax is applicable on PharmEasy Unlisted Shares/Pre IPO Shares?

Short Term Capital Gains Tax: If unlisted shares are sold in 24 months or less, gains from such sale are taxed at the slab rate.

How much LTCG tax is applicable on PharmEasy Unlisted Shares/Pre IPO Shares?

Long Term Capital Gains Tax: If unlisted shares are sold after holding for more than 24 months, gains on such sale will be taxed at 20% after indexation.

What will be the tax applicability if PharmEasy Unlisted Shares gets listed?

Tax on Capital Gains on Unlisted Shares that are sold after getting listed: The tax rates will be the same as that on purchase and sale of listed shares.
That is, the long-term gains (shares sold after holding for more than one year) will be taxed at 10% after a threshold of ₹ 1 lakh per financial year.
Short-term gains (gains on selling shares in one year or less) will be taxed at 15%

Where can I find PharmEasy Unlisted Shares price graph?

You can check the historical price trend by checking PharmEasy Unlisted Shares price graph here PharmEasy Unlisted Shares price chart will help you get an idea about price-action. You can also check the current trend of PharmEasy Unlisted Shares here

How to check valuations of PharmEasy Pre IPO Shares?

For listed shares, there are numerous applications and website which shows the market capitalization of shares. But no need to worry, we have included market capitalization scenarios on our website which shows market cap/valuations of the company based on prevailing Unlisted Shares rates. In addition, we have also mentioned total number of shares so that you can easily calculate current market cap quickly without putting much efforts. Click here to see the valuations of PharmEasy Pre IPO shares
Quick tip: Market Cap= Total Outstanding shares x Price per share

How to check latest news and developments related to PharmEasy Unlisted Shares?

You can easily check latest developments, news related to PharmEasy Unlisted Shares on our website without any sign up or login. Click here to know about latest news and happenings

Why trust Unlisted Arena for buying Unlisted Shares and Pre IPO Shares?

Unlisted Arena is a prominent name which facilitates Unlisted Shares & Pre IPO Shares safely and securely. All the transactions are done through bank accounts where no third parties are involved. Unlisted Arena always quotes transparent rates and is also known for its fastest delivery of Unlisted Shares and Pre IPO Shares. Unlisted Arena gets featured regularly in India’s top most financial publications. You can check media coverage of Unlisted Arena here

Is API Holdings a Pre IPO, Unlisted or Delisted share?

API Holdings is a Pre IPO company. API Holdings had plans to get its stock listed on exchanges. For that purpose, API Holdings had filed its IPO DRHP with SEBI

Can NRIs buy PharmEasy Unlisted Shares?

Yes, NRIs can also buy and sell PharmEasy Unlisted Shares just like domestic investors. But their investment is on a non-repatriable basis

How is market price of PharmEasy Unlisted Shares determined?

Like any listed shares, Unlisted Shares price is also determined by demand-supply of Unlisted Shares. Higher the demand, higher the price and vice-versa. The rates of Unlisted Shares are also derived from its performance, corporate actions such as declaration of results, bonus, dividend, etc. Another important aspect is share price/valuation of its listed peer. If the listed business is identical, unlisted companies share price/valuation will too be in similar fashion

What are the brokerage/charges for buying/selling Unlisted Shares/Pre IPO Shares?

At Unlisted Arena, we charge Zero Brokerage/Charges. The rates quoted by us are- net rates, i.e., you do not need to pay any brokerage or charges

How to buy PharmEasy Unlisted Shares in Zerodha/Angel broking/HDFC Securities/Upstox/ICICI Securities or any other demat account?

One can buy PharmEasy Unlisted Shares in any demat account – no matter with which broker you have a demat account. There is no need for separate/special demat account for buying Unlisted Shares.

Are PharmEasy Unlisted Shares and API Holdings Unlisted Shares the same?

Yes, PharmEasy Unlisted Shares and API Holdings Unlisted Shares are indeed the same. API Holdings Limited is the company, while PharmEasy is the name of brand. The ISIN code for these shares is INE0DJ201029, with the ISIN description as “API HOLDINGS LIMITED EQ NEW FV RE. 1/-.”

From where does Unlisted Arena source API Holdings Unlisted Shares?

Unlisted Arena sources API Holdings Unlisted Shares from existing investors looking to liquidate their investment

Will I get dividend, bonus on Unlisted Shares?

Yes, you are eligible to get dividend, bonus and/or any other corporate actions declared by the company. You need to hold the Unlisted Shares in your demat account on the record date declared by the company to be eligible for such corporate actions

PharmEasy TVC Video:

 Explore Other Unlisted & Pre IPO Shares

Join WhatsApp Community
error: Content is protected !!